Apogee Therapeutics, Inc. Seeks Funding for Biologics Development Through Public Offering
SAN FRANCISCO and WALTHAM, Mass. March 05, 2024 Apogee Therapeutics, Inc. (Nasdaq: APGE), a leading clinical-stage biotechnology company specializing in the development of biologics for inflammatory and immunology indications, has announced the commencement of an underwritten public offering of approximately $350.0 million of shares of its common stock. The company also plans to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock.
Apogee Therapeutics Inc.’s recent financial performance indicates positive growth, with a significant increase in cash and cash equivalents by 238.1% in the third quarter of 2023. This growth has contributed to an improved Quick Ratio of 24.62, although it still ranks lower compared to some competitors in the industry. Over the past twelve months, the company’s Quick Ratio has more than doubled, reaching 15.75, but remains below the company’s 12-month average.
Despite these financial metrics, Apogee Therapeutics Inc. aims to secure additional funding through the proposed public offering to support the development of differentiated biologics for the treatment of conditions such as atopic dermatitis, chronic obstructive pulmonary disease, and asthma. The offering is subject to market conditions, and the final terms and size of the offering are yet to be determined.
In conclusion, Apogee Therapeutics Inc.’s announcement of the proposed underwritten public offering reflects the company’s commitment to advancing its innovative biologics pipeline and furthering its mission to address unmet medical needs in inflammatory and immunology indications.
Comments